Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

PureTech floats away

The healthcare firm PureTech went public in June raising about $195 million, noteworthy in particular because Boston-based PureTech eschewed NASDAQ in its home country and chose to list on the London Stock Exchange's (LSE's) main market. The reasoning, the company said, was because investors on the London market were already familiar with the company-creation concept behind PureTech. PureTech's initial public offering is also interesting for the company's business model. Similar to biotech venture capitalists (VCs), PureTech focuses on creating startups, except that VCs generally choose from the myriad proposals pitched their way, whereas PureTech builds companies toward a preselected unmet medical need. It evaluates about 650 ideas a year and its list of advisors includes Christopher Viehbacher, former CEO of Paris-based Sanofi; and Robert Langer, PureTech co-founder, professor at Massachusetts Institute of Technology in Cambridge and serial entrepreneur. Run by CEO and co-founder Daphne Zohar, PureTech also differs from VCs in that it usually retains around 80% ownership in its companies. That makes PureTech's goal, Zohar says, the same as a typical biotech's—get products to market. Although PureTech could sell a company or push it public in the manner of a VC, by retaining majority ownership of its projects, PureTech's bottom line benefits directly from its products through revenues, royalties or licensing income. This bottom line is what PureTech's new shareholders will now be watching.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

PureTech floats away. Nat Biotechnol 33, 792 (2015). https://doi.org/10.1038/nbt0815-792a

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing